Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 02, 2015 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease

CARMIEL, Israel, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company has completed enrollment in its phase I/II clinical trial...
January 08, 2015 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease

Meaningful Clinical Benefits Demonstrated Across All Key Disease Parameters Favorable Safety Profile CARMIEL, Israel, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE...
January 05, 2015 09:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the 2015 J.P. Morgan Healthcare Conference

CARMIEL, Israel, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Moshe Manor, the Company's President and Chief Executive Officer, will...
January 05, 2015 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces New Strategy for Accelerated Growth

CARMIEL, Israel, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today the Company's newly implemented strategy for accelerated growth. The...
September 29, 2014 02:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Appoints Moshe Manor as President and Chief Executive Officer

CARMIEL, Israel, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that its Board of Directors has appointed Mr. Moshe Manor as its new...
September 04, 2014 07:36 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

CARMIEL, Israel, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Yossi Maimon, the Company's Chief Financial Officer, will present at...
August 28, 2014 17:50 ET | Source: Protalix BioTherapeutics, Inc.

Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs

CARMIEL, Israel, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it will host a conference call on Wednesday, September 3, 2014 at...
July 24, 2014 08:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors

CARMIEL, Israel, July 24, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it has chosen Mr. Shlomo Yanai as Chairman of the Company's Board of...
June 27, 2014 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

CARMIEL, Israel, June 27, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSOTM (taliglucerase alfa) will be presented...
June 23, 2014 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces New Data on ELELYSO(TM) (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th Meeting

CARMIEL, Israel, June 23, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on ELELYSO™ and oral glucocerebrosidase (GCD),...